Mersana Therapeutics (MRSN) Misses Q2 EPS by 3c

Mersana Therapeutics (NASDAQ: MRSN) reported Q2 EPS of ($0.20), $0.03 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $2.3 million versus the consensus estimate of $8.72 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.

You May Also Be Interested In

• Microsoft Replaces OpenAI, Anthropic With Own AI in Some Apps - Bloomberg
• FDA grants accelerated approval to Vera Therapeutics' kidney drug
• RxSight Inc. (RXST) PT Lowered to $6.50 at BofA Securities